Trial Profile
Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OSAT
- Sponsors Novartis Pharmaceuticals
- 12 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Nov 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 04 Nov 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.